Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acazicolcept - Vertex Pharmaceuticals

Next Previous
Drug Profile

Acazicolcept - Vertex Pharmaceuticals

Alternative Names: Acazicolceptum; ALPN 101; CD28/ICOS antagonist - Vertex Pharmaceuticals; Dual CD28/ICOS inhibitor - Vertex Pharmaceuticals; ICOS/CD28-antagonist- Vertex Pharmaceuticals

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alpine Immune Sciences
  • Developer Vertex Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Immunoglobulin fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action CD28 antigen inhibitors; Inducible T-cell co-stimulator protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Preclinical Arthritis
  • No development reported Autoimmune disorders; Connective tissue disorders; Graft-versus-host disease; Haemophagocytic lymphohistiocytosis; Inflammation; Inflammatory bowel diseases; Multiple sclerosis; Psoriatic arthritis; Sjogren's syndrome; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral)
  • 28 Jul 2025 No recent reports of development identified for preclinical development in Uveitis in USA (Parenteral)
  • 09 Jul 2024 Vertex Pharmaceuticals completes the Phase-II Synergy trial in Systemic lupus erythematosus in France, Hungary, South Korea, Poland, Puerto Rico, Spain, Taiwan, and the US (NCT04835441),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top